EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 642 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Final OS and the Exploratory Analysis of the Outcome with Osimertinib... February 13, 2024 Front-line CS1001 Plus Platinum-Based Chemotherapy Delivers Substantial Benefit in Advanced Non-Small... November 21, 2020 A new IARC live webinar on evidence in primary cancer prevention November 11, 2021 ESMO Targeted Anticancer Therapies Congress 2024, 26-28 February, Paris, France February 20, 2024 Load more HOT NEWS Long-Term Follow-Up Confirms Pembrolizumab and Pembrolizumab-Chemotherapy as Effective First-Line Treatment Options... FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer Finding Hope in the New Year During COVID-19 and Cancer ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)
